Tirzepatide 'overdose' on TikTok: what actually happened?
Quick answer
The creator describes nine weeks of unintentional tirzepatide overdosing due to a unit-to-milligram conversion error, presenting with acute symptoms including severe nausea and refractory headache consistent with dose-dependent GLP-1 receptor agonist adverse effects. She also carries a type 1 diabetes designation, which is clinically significant because tirzepatide is not FDA-approved for type 1 diabetes and concurrent insulin use raises hypoglycemia risk that she does not address. Her reported 5-day recovery timeline aligns with tirzepatide's approximately 5-day half-life.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @amberlykins actually say?
She's been dosing tirzepatide incorrectly for nine weeks and only just figured it out. In her words, she "did it wrong for nine weeks" and "just did my tenth shot correctly." The video caption confirms she was taking more than intended, referencing 25 units (2.5mg) as the correct dose. On day 66 of her journey, she's filming from what sounds like a bed, nauseated, with a headache so severe it took her 30 minutes to wash her face. She also reports being down 10 pounds, from 159 to 150. Critically, she has a type 1 diabetes hashtag on her video, which adds a layer of clinical complexity that she does not address at all in the transcript.
To be clear about what she's documenting: nine weeks of an unintended higher dose, followed by acute side effects severe enough to miss church and struggle with basic self-care tasks.
Does the science back this up?
Yes, mostly. The side effect profile she's describing is textbook tirzepatide overdose territory, and the research supports that. The SURPASS trial series (Dahl et al., 2022, The Lancet) consistently showed nausea, vomiting, and headache as the most common adverse events, dose-dependent and most severe during dose escalation. What she experienced, severe nausea and a pounding headache that ibuprofen couldn't touch, fits this pattern precisely.
The weight loss she reports, 10 pounds over roughly 9 weeks, is plausible but on the modest end compared to trial data. SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed average losses of 15-20% body weight over 72 weeks at therapeutic doses. At a starting weight of 159 pounds, losing 10 pounds in roughly 9 weeks is real but not exceptional. The complicating factor no one in the comments is probably saying: if she was accidentally overdosing for nine weeks, some of that weight loss may have come from nausea-driven caloric restriction, not the drug's metabolic mechanism alone.
What did they get wrong (or right)?
She got the acknowledgment right. Admitting on camera that you've been dosing a prescription medication incorrectly for over two months takes some courage, and it's genuinely useful for other people who might be making the same mistake with unit-to-milligram conversions on insulin syringes, which is a known and documented source of tirzepatide dosing errors with compounded versions.
What she got wrong, or at minimum dangerously incomplete: she has a type 1 diabetes hashtag on this video and says nothing about it in her narration. Tirzepatide is not approved for type 1 diabetes. The FDA label explicitly excludes it from this population, and there are real concerns about hypoglycemia risk in type 1 patients using GLP-1 receptor agonists alongside insulin (Mathieu et al., 2021, Diabetes Care). Framing an overdose recovery as "good news, I'm 100% better" without addressing any of that is a meaningful omission for a video that 93,000 people have watched.
Taking ibuprofen for a headache while nauseated and likely dehydrated is also not ideal, since NSAIDs can worsen GI distress, but she's not presenting herself as medical advice, to be fair.
What should you actually know?
Dosing errors with compounded tirzepatide are a real and underreported problem. Because compounded versions are often sold in multi-dose vials measured in milligrams per milliliter, users drawing doses with insulin syringes in units can easily miscalculate. The FDA issued a safety communication in 2024 specifically about this risk with compounded GLP-1 medications, citing reports of accidental overdoses resulting in severe nausea, vomiting, and hypoglycemia.
Her recovery taking about 5 days also tracks. Tirzepatide has a half-life of approximately 5 days (Coskun et al., 2022, Clinical Pharmacokinetics), so one week after an accidental higher dose, you would expect symptoms to substantially resolve as the drug clears.
- Compounded tirzepatide is not the same as Mounjaro or Zepbound. Bioequivalence has not been established.
- Unit-to-milligram conversion errors are the most common source of overdose in at-home GLP-1 use.
- Severe headache and nausea post-injection should prompt a call to your prescriber, not ibuprofen and a TikTok.
- Type 1 diabetes and tirzepatide is a complex combination that requires physician oversight, not hashtags.
Bottom line
This video is a useful real-world account of what a tirzepatide dosing error looks like from the inside. The symptoms are consistent with the literature. The transparency is commendable. But 93,000 viewers are watching someone with type 1 diabetes describe an overdose recovery as essentially a minor inconvenience, and that framing deserves more scrutiny than the comment section is probably giving it. If you are using compounded tirzepatide at home, triple-check your unit-to-milligram conversion with your prescribing provider before every dose change.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Tirzepatide 'overdose' on TikTok: what actually happened?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Claim verdict
The useful answer behind this video
Claim being checked
The creator describes nine weeks of unintentional tirzepatide overdosing due to a unit-to-milligram conversion error, presenting with acute symptoms including severe nausea and refractory headache consistent with dose-dependent GLP-1 receptor agonist adverse effects.
FormBlends verdict
The creator describes nine weeks of unintentional tirzepatide overdosing due to a unit-to-milligram conversion error, presenting with acute symptoms including severe nausea and refractory headache consistent with dose-dependent GLP-1 receptor agonist adverse effects. She also carries a type 1 diabetes designation, which is clinically significant because tirzepatide is not FDA-approved for type 1 diabetes and concurrent insulin use raises hypoglycemia risk that she does not address. Her reported 5-day recovery timeline aligns with tirzepatide's approximately 5-day half-life.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator describes nine weeks of unintentional tirzepatide overdosing due to a unit-to-milligram conversion error, presenting with acute symptoms including severe nausea and refractory headache consistent with dose-dependent GLP-1 receptor agonist adverse effects. She also carries a type 1 diabetes designation, which is clinically significant because tirzepatide is not FDA-approved for type 1 diabetes and concurrent insulin use raises hypoglycemia risk that she does not address. Her reported 5-day recovery timeline aligns with tirzepatide's approximately 5-day half-life.
- The FDA issued a 2024 safety communication specifically about dosing errors with compounded GLP-1 medications, citing unit-to-milligram miscalculations as the primary cause of accidental overdoses.
- Tirzepatide has a half-life of approximately 5 days (Coskun et al., 2022, Clinical Pharmacokinetics), which explains why symptoms from a single overdose largely resolve within one week.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- The FDA issued a 2024 safety communication specifically about dosing errors with compounded GLP-1 medications, citing unit-to-milligram miscalculations as the primary cause of accidental overdoses.
- Tirzepatide has a half-life of approximately 5 days (Coskun et al., 2022, Clinical Pharmacokinetics), which explains why symptoms from a single overdose largely resolve within one week.
- Nausea and headache are the most common adverse events in tirzepatide trials and are dose-dependent, meaning a higher-than-intended dose predictably worsens both (Dahl et al., 2022, The Lancet).
- Tirzepatide is not FDA-approved for type 1 diabetes, and concurrent use with insulin carries hypoglycemia risk that requires physician oversight, not self-managed dosing adjustments.
- Compounded tirzepatide has not been shown to be bioequivalent to branded Mounjaro or Zepbound. They are not interchangeable, and dosing instructions may differ between formulations.
- A 10-pound weight loss over 9 weeks at 159 lbs starting weight is plausible but may partly reflect nausea-driven caloric restriction from an overdose rather than the drug's intended metabolic mechanism.
- Severe GLP-1 side effects like a headache unresponsive to ibuprofen warrant a call to your prescriber, not self-management at home followed by a social media post.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Amber Lykins · TikTok creator
93.1K views on this video
Day 66: I OVERDOSED and didn’t realize it until after a few mins. I should have taken 25unit (2.5mg). I wont do that again. GOOD NEWS: its been 5 days and im 100% better- ill have a video coming on all of that but im down 10lbs officially. Started at 159(160 depending on day), now at 150!!! 👏🏻👏🏻👏🏻 #tirzepatide #amberlykins #type1diabetes
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Amber Lykins, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.